Survodutide: Dosage & Administration
Part of the Survodutide Complete Guide
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
Dosage Protocols
| Indication | Dose Range | Route | Frequency |
|---|---|---|---|
| Obesity (Phase 2) | 0.3–6 mg | SC injection | Weekly |
| MASH (Phase 2) | 2.4–6 mg | SC injection | Weekly |
Dose escalation over several weeks to target dose. The 4.8 mg dose showed the best balance of efficacy and tolerability in Phase 2 MASH trials.
Administration
Clinical trial formulations are pre-filled. Not available as a research compound. Subcutaneous injection administration.
Timing
Weekly injection. Phase 2 MASH trial duration was 48 weeks. Long-term use anticipated.
Storage
- Clinical formulations: refrigerate at 2–8°C
- Do not freeze